Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin

Abstract

Stage II and III HER2-positive breast cancer patients achieved a high rate of PCR with trastuzumab given concurrently with paclitaxel and FEC(75) chemotherapy. No severe cardiac events were observed with the regimen. The data concur with the results of a previously published trial.